OTC: BRGX

The Company, through its subsidiaries, engages in research, development,
and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies. The Company and its
subsidiaries are conducting clinical studies related to certain products; however, such studies are ongoing and there can be no assurance
that they will demonstrate efficacy or support regulatory acceptance.

The Company’s products and operations are subject to regulation
by the U.S. Food and Drug Administration and other federal and state authorities. The Company’s medical device, software, and contactless
diagnostic offerings, including those classified as Class I devices, are subject to applicable regulatory requirements, which may include
registration, listing, labeling, quality system regulations, and, in certain cases, premarket review or clearance. The Company’s
dietary supplements are regulated as foods and must comply with labeling and current Good Manufacturing Practice requirements. Statements
regarding potential health benefits have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

In addition, the Company’s telehealth, wellness, and diagnostic
activities may be subject to federal and state laws governing licensure, patient privacy (including the Health Insurance Portability and
Accountability Act), and the provision of healthcare services. Compliance with these requirements may necessitate additional approvals
or clearances, and changes in the regulatory environment could materially affect the Company’s business, financial condition, and
results of operations.

OPERATING SUBSIDIARIES

DocSun BioMedical Holdings, Inc.

On January 8, 2024, pursuant to a Securities Exchange
Agreement effective November 15, 2023 and an Addendum to the Securities Exchange Agreement dated December 5, 2023, BioRegenx acquired
DocSun Biomedical Holdings, Inc. Pursuant to the Securities Exchange Agreement, BioRegenx acquired all of the issued and outstanding securities
of DocSun in exchange for 76,800,000 BioRegenx common shares.

1

Technology

DocSun combines three technologies in the DocSun
Artificial Intelligence (AI) Engine. The DocSun AI Engine integrates advanced ballistocardiography, which can detect an individual's heartbeat
without touch, and photoplethysmography, a method that uses light to track the flow of blood. These methodologies are further enriched
with the decoding capabilities of optical coherence tomography, a technique that creates detailed images of structures inside the body.
This combination is meticulously designed to harness the power of artificial intelligence for vital sign estimation.

By deploying a strategic facial scanning technique,
the engine captures and analyzes nuanced physiological signals. This not only facilitates the extraction of vital signs but also ensures
a non-invasive, user-friendly approach to health monitoring, embodying a confluence of technology and practical applicability in the realm
of remote health diagnostics.

Sales and Marketing

DocSun's engineering team is actively engaged in installing
new hardware and coding software to enhance AI capabilities, paving the way for future growth opportunities.

Contracts

DocSun entered into a technical services agreement
with a large software technology company to provide technical services in China, Hong Kong and Macao. This agreement involves supplying
DocSun's AI Engine technology to the distributor targeting multiple sectors, including the latest release of DocSun’s Software Development
Kit (SDK). Initial revenues stem from the testing of DocSun's SDK in fleet and electric vehicles (EV's) amongst other applications, with
commercialization slated to begin in late third quarter or early fourth quarter. As per the agreement terms, which was entered on August
30, 2023, DocSun is entitled to a signing fee of $200,000 (payable over ten months) and will receive a 40% of all the revenue generated
including 40% of the $10 per vehicle license fee from the EV automotive manufacturer. The term of the agreement commences upon receipt
of the first installment of the signing fee and is for a period of five years. To date, DocSun has not received fees under this agreement.

On October 16, 2023, DocSun entered into a License
Agreement with NuLife Sciences, Inc. under which it granted NuLife a world-wide non-exclusive license to use our technology. DocSun shall
receive a license fee of $3.50 per subscriber. The first demo scan is complimentary for each unique email address. The agreement will
continue for an initial period of three years and will automatically renew for periods of three years unless either party gives notice
of non-renewal to the other party at least thirty days prior to the end of any three-year term.

DocSun is developing an app for NuLife Sciences -
TruScan.Ai mobile app/website. The development encompasses:

(a) Incorporating DocSun's AI Engine: A pivotal integration,
enabling the platform to deliver 21 critical health indications, ensuring comprehensive and accurate health monitoring.

(b) User-Experience (UX) Design: Seamless Navigation,
Personalized Monitoring

DocSun is sculpting an intuitive and accessible interface,
meticulously designed to cater to users across all demographics, ensuring effortless navigation and utilization of the platform. DocSun’s
focus is to empower users with the ability to:

(c) Monitor Holistically: View and analyze their health
metrics not just as standalone figures, but as a comprehensive, easy-to-understand narrative, whether they choose to explore it daily,
monthly, or across custom-defined periods.

(d) Historical Wellness Tracking: A dedicated section
for users to effortlessly scroll through their past wellness scans, juxtaposed with the latest data, enabling them to observe, compare,
and comprehend their wellness journey over time.

2

(e) Engaging Visuals: Employing vibrant, yet non-intrusive
visuals to represent data, ensuring users can at a glance, comprehend their health status and any fluctuations therein.

(f) Personalized Alerts: Tailoring notifications and
alerts to keep users abreast of their wellness, gently nudging them towards maintaining or enhancing their health metrics and potential
products.

Through these, DocSun’s aim is to not just provide
data but to enhance user engagement, making health monitoring not a task, but an engaging, insightful experience. The development of this
application is ongoing.

(g) Integration with VitalWellness mobile app: A crucial
phase of the development involves seamless integration into the VitalWellness mobile app, ensuring that the rich functionalities and health
indications of TruScan.Ai are accessible to users across both Apple and Android platforms. This integration is not just about data sharing
but ensuring that user experiences are unified and coherent across platforms, providing a consistent and reliable health monitoring experience.

Revenues

DocSun will derive revenues under the terms of the
distribution agreement described above and from the licensing of its technology. To date, DocSun has not generated revenue.

MICROVASCULAR HEALTH SOLUTIONS™ LLC

Microvascular Health Solutions, LLC (MVHS) specializes
in research, product development, sales, and education, notably producing the patented Endocalyx Pro™ dietary supplement. MVHS also
manufactures and distributes the patented GlycoCheck™ software and Class 1 medical device. Presently, MVHS actively participates
in multiple double-blind placebo studies worldwide, exploring the impact of Endocalyx Pro™ on various health conditions while maintaining
compliance with GMP regulations.

Patents

The Company has patents and pending patents on Endocalyx
Pro™ in North America, Asia and Europe

Products

Endocalyx Pro™. Endocalyx Pro™
is a dietary supplement targeting microvascular capillary health.

Production. Our supplement is produced by a fully
accredited and certified manufacturing facility. Our source has provided outstanding contract manufacturing, formulation expertise, and
custom finishing and packaging to the dietary supplement industry. They specialize in encapsulation, tablet compression, powder blending
and filling, and product development. The company is currently in discussions with other fully accredited and certified manufacturing
facilities for future expansion.

Distribution. Distribution is handled at the Company’s
headquarter in Chattanooga, TN and by Midstates Fulfillment, Aberdeen, SD.

Sales and marketing. The supplement has achieved monthly
sales figures that have demonstrated consistency in demand.

Additional supplements. NuLife Sciences, a
MVHS sister company, offers a range of supplements under the MyBodyRx® brand.

3

Wholly Owned Subsidiary

MyBodyRx, LLC (MyBodyRx) is a sales and product development
company that produces dietary supplements that complement and work synergistically with the patented and clinically tested Endocalyx Pro™
to support and improve healthy aging and increase longevity.

MyBodyRx® products are produced by
a fully accredited and certified manufacturing facility. Our source has provided outstanding contract manufacturing, formulation expertise,
and custom finishing and packaging to the dietary supplement industry. They specialize in encapsulation, tablet compression, powder blending
and filling, and product development.

Revenues

MVHS and the Company derives revenue from sales of
GlycoCheck™ systems to academic research hospitals and groups, private medical practices, pharmacies, dentists, and wellness practitioners.
In addition, revenue is derived from sales of Endocalyx Pro™ to medical wholesalers and resellers.

MVHS commenced sales by fulfilling pre-orders and
continues to deliver on new sales, with GlycoCheck system packages priced between $14,900 to $32,000, generating monthly recurring revenue
based on scans performed. Favorable financing options have been secured for GlycoCheck customers, ensuring accessibility and affordability.

NULIFE SCIENCES™, INC.

NuLife Sciences, Inc. (NuLife) functions as a marketing
and distribution enterprise, aiming to redefine health and longevity by leveraging advanced technologies. NuLife markets the MyBodyRx®
branded supplement line, that includes our patented product Endocalyx Pro™ and also markets GlycoCheck™ along with other health
and wellness devices.

In addition to the line of the MyBodyRx®
branded products offered, NuLife markets hydrogen water products, health and wellness devices such as Pulsed Electro-Magnetic Field devices
and StimaWELL and ReLounge, class II Electronic Muscle Stimulation therapy devices through a network of affiliates, practitioners, and
consumers. NuLife is currently developing health and wellness apps with a technology company which will provide DNA and epigenetics testing
products and services. These therapies cater to a wide array of health indications, promoting overall well-being.

TruScan.Ai mobile app/website.

NuLife is working in collaboration with DocSun to
develop its TruScan.AI mobile app integrating DocSun’s AI engine. The platform is designed to seamlessly integrate additional health
indications as they are developed and released by Licensor in the future. TruScan.Ai mobile app will incorporate health indicators in
the following four sectors: vitals, nutrients, wellness and skin health metrics. The TruScan.Ai mobile app is anticipated for release
in the third quarter of 2027.

VitalWellness mobile app

NuLife is also in development of the VitalWellness
app that will merge its DNA and epigenetics platform with the DocSun technology.

Contracts

NuLife entered into a license agreement with DocSun
to use the DocSun technology and to develop an app/website.

4

Sales and Marketing

In 2025, the Company intensified its sales and marketing
efforts to further boost sales, through new online sales channels, such as Amazon, Walmart and Meta Ads. The new channels are expected
to provide organic growth to overall sales of the Company.

Revenue

Revenue is generated from the sale of goods and services
to doctors, healthcare practitioners, patients, consumers and wholesale distributors.

FINDIT AI CONNECT, INC.

Simultaneously with the closing of the merger on March
8th, 2024, the Company created Findit Ai Connect, Inc. (Findit Ai), a wholly owned subsidiary and capitalized the subsidiary
with the Findit pre-merger assets and liabilities. Findit Ai owns Findit.com and Classworx.com. Findit.com operates as a Social Media
Content Management Platform, that includes its own interactive search engine. Members can utilize the Findit search feature to submit
URLs they want to index in the Findit search results. Nonmembers can come to Findit.com and enter search queries, Findit.com returns matching
search results from content posted in Findit along with outside web pages that have been submitted. The Company is working on adding an
Ai component that will create the member’s posts and automate the distribution of the post across the member’s various connected
social media platforms.

Patents, Trademarks Licenses and Other Intellectual
Property

We own trademarks in “Findit”, “Findit.com” and
“Classworx”.

Products and Services

Both websites are accessible to anyone, this means
you do not need to be a member of the platform to view or search content posted on Findit.com. Anyone that wants to have content indexed
in Findit’s search or viewed by visitors on Findit.com can do so by creating a free account and posting their content to the various
verticals Findit offers.

A Findit member is someone who has created a Findit
account by creating a username and password on the platform. We do not determine, at this time, which members are active and which members
are inactive. We currently do not have code written that provides these analytics. We intend, as funds allow, to bring on additional developers
that will be able to write code that will provide this data.

Revenues

We currently intend to monetize Findit AI Connect
by utilizing its websites and platforms within the Company’s marketing efforts, through online content marketing campaigns, automation
tools offered to our various affiliate partners and to promote and sale our online products and services along with third party monetization
or white label licenses of the Findit Ai Connect tools.

5

MARKET SIZE

Overview

The global healthcare market is experiencing significant
growth, driven by advancements in medical technology, an aging population, and increased health awareness. In 2025, the healthcare services
market was valued at approximately $9.25 trillion, reflecting a compound annual growth rate (CAGR) of 5.4% from $8.77 trillion in 2024.
(a)

A notable segment within this expansive market is
telehealth, which has seen accelerated adoption due to technological innovations and the demand for remote healthcare solutions. In 2025,
the global telehealth market was valued at $181.41 billion and is projected to grow to $219.31 billion in 2026, with an anticipated CAGR
of 24.6%, reaching $1,272.81 billion by 2034. (b)

Trends and Growth Potential

·
Telehealth and Remote Monitoring: The shift towards remote healthcare services has led to significant growth in the telehealth sector. The U.S. telehealth market alone is expected to be valued at $51.5 billion in 2025 and is expected to grow at a CAGR of 23.8% from 2025 to 2030. (c)

·
Preventive Healthcare: There is a growing emphasis on preventive healthcare, with individuals increasingly seeking proactive measures to maintain health and prevent disease. This trend is fostering opportunities for innovative solutions in health monitoring and early intervention.

MARKET STRATEGY

Our company and its subsidiaries employ a comprehensive
approach that integrates business-to-business (B2B) and business-to-consumer (B2C) strategies, targeting key markets such as academic
research institutions, medical professionals, cybersecurity sectors (including liveness detection and anti-spoofing), and direct-to-consumer
initiatives.

Marketing Strategies:

·
Professional Engagement: Strengthen relationships with healthcare practitioners through training sessions, seminars, webinars, and participation in industry events.

·
Research Collaboration: Partner with researchers to conduct studies utilizing GlycoCheck™ to explore links between microvascular health and various conditions.

·
Clinical Trials: Support double-blind placebo studies of Endocalyx Pro™ to validate efficacy and safety.

·
Technology Promotion: Highlight DocSun's AI technology as a cutting-edge solution across healthcare, transportation, insurance, and cybersecurity sectors.

·
Affiliate Programs: Collaborate with nutritionists and wellness influencers to create synergistic marketing and educational distribution channels.

·
Digital Outreach: Utilize webinars and social media campaigns to engage healthcare influencers and professionals, showcasing the capabilities of the DOCSUN AI Engine.

·
App Integration: Promote the integration of TruScan.Ai within the VitalWellness App through targeted advertising and influencer testimonials.

Sales and Distribution:

·
Academic Sales: Continue supplying academic researchers worldwide to validate scientific methodologies.

·
Healthcare Facilities: Expand sales to healthcare institutions, diagnostic laboratories, and emergency care units.

·
Direct-to-Consumer: Enhance direct sales channels to reach end-users effectively.

·
Wholesale Distribution: Partner with supplement wholesalers to broaden market reach.

·
Clinical Partnerships: Collaborate with practitioner clinics to offer products directly to patients.

·
Wellness Collaborations: Establish partnerships with wellness centers and genetic testing providers to increase accessibility.

·
B2B Sales: Market the DOCSUN AI Engine to healthcare institutions, leveraging influencer partnerships within the gig economy.

·
B2C Distribution: Distribute VitalWellness and TruScan apps through online app stores to reach a broad consumer base.

_______________

(a)
Healthcare Services Global Market Report 2025. https://www.researchandmarkets.com/reports/5781185/healthcare-services-market-report?

(b)
Fortune Business Insights Telehealth Market Report. https://www.fortunebusinessinsights.com/industry-reports/telehealth-market-101065

(c)
Grand View Research Market Analysis Report. https://www.grandviewresearch.com/industry-analysis/us-telehealth-market

6

Pricing Strategies and Positioning:

·
Recurring Revenue: Implement a subscription-based model for GlycoCheck™ software services.

·
Supplement Sales: Drive recurring sales through practitioner recommendations and direct-to-consumer channels for supplement products.

·
Product Extensions: Develop synergistic supplement products to enhance the existing portfolio.

·
Profit Sharing: Enable wholesalers and influencers to earn profits on sales to encourage ongoing engagement.

·
Premium Positioning: Position the DOCSUN AI Engine as a premium solution for healthcare professionals and applications in security and law enforcement.

·
Competitive Pricing: Offer the Vital Wellness App at a competitive price point to encourage widespread adoption.

COMPETITION

The health, wellness, and anti-aging markets are highly
competitive, characterized by a mix of well-established domestic and international market participants. Many companies within these industries
employ various growth strategies, including acquisitions, partnerships, and new product launches, to strengthen their market position.
(d)

All aspects of the health, nutritional, supplement,
and medical device industries are highly competitive. Our subsidiaries compete with large, well-established firms that possess substantially
greater financial, technical, and personnel resources. Competitive factors in our industry include industry experience, business execution
capabilities, and the strength of client relationships. Intense competition may negatively impact our subsidiaries' operations and market
share.

We face significant competition across multiple aspects
of our business, particularly from major technology and digital marketing companies such as Alphabet Inc. (Google), Microsoft Corporation,
Meta Platforms (Facebook, Instagram), X Corp. (formerly Twitter), and Zillow. These competitors offer a variety of internet-based services,
digital marketing platforms, and online advertising tools, many of which overlap with our content distribution and marketing services.
We also compete with traditional and online media companies for user engagement and content distribution.

Certain competitors, particularly those with dominant
market positions, may leverage their extensive resources and established user bases to develop products or services that compete directly
with our offerings. For example, Google could utilize its search capabilities to create a competing feature similar to Findit, allowing
users to index web pages under custom titles and descriptions. Additionally, existing or emerging social networking platforms could introduce
features mirroring Findit's functionalities, potentially impacting our market presence and growth trajectory.

Factors Influencing Competitive Positioning

We believe that our ability to compete effectively depends on multiple
factors, both within and beyond our control, including:

·
The usefulness, ease of use, performance, and reliability of our products compared to competitors.

·
The size, composition, and engagement levels of our user base.

·
The timing and market acceptance of our products and technologies.

·
Our ability to effectively monetize our products and services, including the successful monetization of app usage.

_______________

(d)
Mordor Intelligence Report Anti-Aging Market https://www.mordorintelligence.com/industry-reports/anti-aging-market

7

Competitive Landscape by Market Segment

Anti-Aging and Preventive Health

Competition in this sector remains intense, encompassing
established skincare and wellness brands, pharmaceutical companies, and emerging technology-driven anti-aging solutions.

Health and Wellness Industry

The health and wellness sector is highly competitive,
with challenges related to differentiation, innovation, and customer acquisition. The Company’s products and services compete with
a broad range of industry participants, from traditional healthcare providers to digital health startups specializing in telehealth, AI-driven
diagnostics, and personalized wellness solutions.

Search Engine and Digital Advertising Competition

The Company also competes in the search engine and
digital advertising markets, where companies such as Google, Bing, Yahoo, and emerging AI-powered search platforms dominate. These companies
provide search engine indexing, online advertising services, and algorithm-driven content discovery tools that influence web traffic and
visibility. Our competitive positioning in this space depends on our ability to enhance search engine discoverability, optimize content
distribution, and offer unique value propositions that differentiate us from larger incumbents.

Telehealth and Remote Monitoring Competition

The telehealth industry has witnessed rapid expansion,
with leading players such as Teladoc Health, Amwell, MDLIVE, and emerging AI-driven telehealth platforms competing for market share. Our
competitive differentiation in this space is driven by our proprietary AI technology, strategic partnerships with healthcare providers,
and our focus on preventive healthcare solutions. As the telehealth market evolves, regulatory compliance, data security, and technological
advancements will remain key factors in determining long-term success.

Competitive Advantages

Pricing Strategies and Market Positioning

·
Synergistic product formulations strategically positioned across multiple sales channels.

·
Competitive pricing strategies for the VitalWellness App to drive widespread adoption among consumers and gig economy professionals.

Operational Efficiency and Technological Edge

We have implemented advanced operational systems designed
to streamline manufacturing, optimize supply chain management, and enhance product development. These efficiencies allow us to provide
high-quality products and services at competitive price points.

8

Employees

As of December 31, 2025, the Company and its subsidiaries
employed six full-time employees and eight independent contractors. Additionally, strategic outsourcing is utilized to optimize resource
allocation and operational efficiency.

Financial Information by Geographic Area

For the fiscal years ended December 31, 2025, and
December 31, 2024, revenue from United States customers accounted for approximately 93% and 88% of total Company revenue, respectively.
International market expansion remains a key focus area for future growth.

Implications of Being an “Smaller Reporting
Company”

Certain reduced reporting requirements and exemptions
are available to us due to the fact that we qualify as a “smaller reporting company” under SEC rules. For instance, smaller
reporting companies are not required to obtain an auditor attestation report regarding management’s assessment of internal control
over financial reporting; are not required to provide a compensation discussion and analysis; are not required to a pay-for-performance
graph or CEO pay ratio disclosure; and may present only two years of audited financial statements and related MD&A disclosure. Investors
should be aware that we are subject to the "penny stock" rules adopted by the Securities and Exchange Commission, which regulate
broker-dealer practices in connection with transactions in Penny Stocks. These regulations may have the effect of reducing the level of
trading activity, if any, in the secondary market for our stock, and investors in our common stock may find it difficult to sell their
shares.

Available Information

The Company maintains its website at the following
address:

www.bioregenx.com

Our Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed
or furnished pursuant to Sections 13(a), 14, and 15(d) of the Exchange Act are available through the “Investors” portion of
our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities
and Exchange Commission, or SEC. Information on our websites is not part of this Annual Report or any of our other securities filings
unless specifically incorporated herein by reference. We have included our website address in this Annual Report solely as inactive textual
references. Our filings with the SEC may be accessed through the SEC’s website at www.sec.gov. All statements made in any of our
securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement
is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to
do so by law.